Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Nordiccan A/S is active in the Biotechnology & Pharmaceuticals technology area. The company's patent portfolio currently features 1 pending office action. This indicates a targeted prosecution effort within the pharmaceutical sector for the company's current filings.
The examination of this portfolio is handled by 1 distinct examiner and 1 distinct art unit. This focus implies that the technical content of the filings remains within a single department's expertise. Such a structure simplifies the management of the prosecution timeline and examiner communications.
CHI, AMANDA LYNN is the busiest examiner, with 1 busiest examiner pending office action currently assigned. This examiner manages the total active workload for the portfolio. The prosecution strategy for Nordiccan A/S is currently centered on the requirements of this specific examiner.
The absence of multiple art units suggests a very specific technical focus for the company. Because there is 1 distinct examiner, the applicant can tailor their arguments to a single set of preferences. This concentration of 1 pending office action under 1 examiner creates a highly localized prosecution environment.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHI, AMANDA LYNN | 1 | — | — |
| Art Unit | Apps |
|---|---|
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18175110 | Fast Disintegrating Cannabinoid Tablets | CHI, AMANDA LYNN | 1600 | §103Other | Final Rejection | — | Pending | Feb 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNordiccan A/S has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Amanda Lynn Chi has the most, with 1 of Nordiccan A/S's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
